Aqtual, a precision medicine company developing diagnostic tests for chronic diseases, raised a $31 million Series B.
Why it matters: The funds will help commercialize its rheumatoid arthritis diagnostic next year, at which point Aqtual will start Series C fundraising, CEO Diana Abdueva tells Axios Pro.
